Barcelona, 19 April 2022– Research has revolutionised cancer treatment in recent years. As a result, we have come to understand…
The use of PARP inhibitors has proven effective in treating patients with homologous recombination deficiency (HRD) tumours such as some…
The results of the Phase III CheckMate-816 study, in which the Vall d’Hebron Institute of Oncology (VHIO), part of the…
A study performed by the European PEACE consortium, in which the Vall d’Hebron Institute of Oncology (VHIO), part of the…
The main conclusion drawn from the data is that the greater the expression of PD-L1, a protein that acts as…
Recently published as a Review* in the open access journal Cancers, our Director, Josep Tabernero, and co-corresponding authors, VHIO’s Maria…
ONIRIA’s flagship first-in-class molecule, ONR-001, has been designed and developed to block tumor growth by activating the epigenetic enzyme TET2….
The Horizon 2020 funded NoCanTher multi-center Consortium has designed and developed a novel anti-cancer strategy combining the implantation of magnetic…
Now released, a superb documentary entitled José Baselga: Cancer’s Fiercest Opponent beautifully chapters the extraordinary life, career and contributions of…
Recently published online ahead of print in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology*, an Article…
Recently published online ahead of print in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology*, an Article…
Last week celebrated the in-person and online 2022 annual Genitourinary (GU) Cancer Symposium of the American Society of Clinical Oncology…
